ERSP warns Beveragette not to overstate efficacy claims
This article was originally published in The Tan Sheet
Executive SummaryBeveragette Ventures can keep marketing claims that its GEM Keep It Cool Menopause Relief Drink reduces symptoms of menopause, but should drop modifiers like "dramatically" and "significantly," the Electronic Retailing Self-Regulation Program says in a report released Feb. 11. The industry watchdog explained the modifiers and testimonials suggesting consumers would receive "immediate results" overstated "the breadth of evidence" the firm submitted. However, the firm provided sufficient data to support claims that its supplement, made mostly of natural extract from black cohosh root, could help alleviate menopause-related hot flashes, night sweats and irritability. Beveragette said it would comply with the recommendations
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.